ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO255

Effects of Intravenous L-Carnitine (LC) Administration in Improving Muscle Strength in Hemodialysis (HD) Patients

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Miyamoto, Takashi, Nagasaki Kidney Center, Nagasaki, Japan
  • Funakoshi, Satoshi, Nagasaki Kidney Center, Nagasaki, Japan
  • Hashiguchi, Jyunichiro, Nagasaki Kidney Center, Nagasaki, Japan
  • Sawase, Kenji, Nagasaki Kidney Center, Nagasaki, Japan
  • Kawazu, Tayo, Nagasaki Kidney Center, Nagasaki, Japan
  • Kubara, Takuya, Nagasaki Kidney Center, Nagasaki, Japan
  • Miyazaki, Sayaka, Nagasaki Kidney Center, Nagasaki, Japan
  • Hayashida, Masatoshi, Nagasaki Renal Center, Nagasaki, Japan
  • Ide, Mashumi, Nagasaki Kidney Center, Nagasaki, Japan
  • Nishino, Tomoya, Nagasaki University School of Medicine, Nagasaki, Nagasaki, Japan
  • Harada, Takashi, Nagasaki Kidney Center, Nagasaki, Japan
Background

Several clinical studies have suggested that LC, a naturally occurring compound involved in bioenergetic processes, may improve muscle function of HD patients. In this study, our aim was to evaluate the effect of intravenous administration of LC on muscle strength measured by isometric handgrip strength (HGS) in HD patients.

Methods

After appropriate IC 172 HD patients on HD were enrolled in this study. Intravenous L-carnitine (1000 mg) was administered after each HD session. HGS was measured using a dynamometer before and 12 weeks after LC administration in female (n=56) and male (n=116) patients of different ages (median age: 68.2±33.3 years) as well as various clinical parameters were determined. Using the Asian Working Group for Sarcopenia criteria the subjects were divided into 2 groups by initial HGS: cut-off score of 18 kilograms (kg) for female and 26 kg for male.

Results

As shown in Figure, significant increase was obtained both in female and male among weaker HGS groups, but not normal HGS groups. There was no significant difference in nutrition parameters such as serum albumin or cholinesterase between weaker and normal HGS groups in females or males.

Conclusion

In our study the administration of intravenous LC has potentially contributes to muscle strength in patients on maintenance HD. LC can be one of the candidates for improving sarcopenia in patients on HD.

Funding

  • Private Foundation Support